Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03644589
Title Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Washington
Indications

triple-receptor negative breast cancer

Therapies

Cisplatin + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.